3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
131
Neoplasms, Plasma Cell
21
Recurrence
20
Lymphoma
14
Lymphoma, Non-Hodgkin
13
Leukemia, Lymphocytic, Chronic, B-Cell
13
Leukemia, Myeloid, Acute
12
Burkitt Lymphoma
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Myeloproliferative Disorders
11
Lymphoma, Mantle-Cell
11
Lymphoma, Follicular
11
Lymphoma, B-Cell, Marginal Zone
11
Leukemia
11
Neoplasms
10
Lymphoma, Large-Cell, Immunoblastic
10
Lymphoma, Large B-Cell, Diffuse
10
Hodgkin Disease
10
Primary Myelofibrosis
9
Myelodysplastic Syndromes
9
Leukemia, Myelomonocytic, Chronic
9
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
9
Congenital Abnormalities
9
Waldenstrom Macroglobulinemia
8
Sezary Syndrome
8
Pdgfra-Associated Chronic Eosinophilic Leukemia
8
Mycosis Fungoides
8
Lymphoma, T-Cell, Cutaneous
8
Leukemia, Neutrophilic, Chronic
8
Leukemia, Myeloid, Accelerated Phase
8
Interventions
ogalvibart
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Purpura, Thrombotic Thrombocytopenic
×
Plasma cell
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn